Criteria to qualify for this study: Drug used in study:
  • If WM with no prior therapy must be considered inappropriate candidates for treatment with standard chemoimmunotherapy regimen

LYM 129 BGB-3111-302 BeiGene

A Phase 3, Randomized, Open-label, Multicenter Study comparing the efficacy and safety of Bruton's Tyrosine Kinase (BTK) inhibitors BGB-3111 and ibrutinib in subjects with Waldenstrom's Macroglobulinemia.